AstraZeneca Pharma India Gets CDSCO Nod for Lynparza Cancer Drug

26 Nov 2024 , 11:42 PM

AstraZeneca Pharma India Ltd. has received approval from CDSCO to import and sell Lynparza (Olaparib) in India.

Lynparza will be available in 100 mg and 150 mg doses in film-coated tablets. It is used with Durvalumab to treat advanced or recurrent endometrial cancer in patients whose disease has not progressed after first-line treatment.

The approval clears the way for AstraZeneca to launch Lynparza in India, offering a new treatment for cancer patients. AstraZeneca also got approval to sell Breztri Aerosphere, a COPD treatment, and plans to launch it in January 2025. AstraZeneca Pharma India focuses on oncology, cardiovascular diseases, and respiratory treatments. The company was also involved in developing the Oxford-AstraZeneca Covid-19 vaccine.

In the national stock exchange, shares of AstraZeneca Pharma India Ltd closed at ₹6472 which is a 0.24% gain than the previous close. The stock has gained a total of 36% in the last one year.